What we're about
Advancing prediction, prevention, and precision therapy for patients with rheumatic diseasesWho we are
Over 200 researchers spanning the basic, clinical, and analytical sciencesHow we help
World-class core facilities and investigator support to drive groundbreaking research and launch distinctive careersWhy we care
Patients with rheumatic diseases need better tests and personalized treatments so they can live healthier, longer lives
Recent Publications
- 47XXY and 47XXX in Scleroderma and Myositis March 30, 2022
- Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus January 10, 2022
- Quantifying Chemical Composition and Reaction Kinetics of Individual Colloidally Dispersed Nanoparticles December 28, 2021
- Nucleic Acid-Sensing and Interferon-Inducible Pathways Show Differential Methylation in MZ Twins Discordant for Lupus and Overexpression in Independent Lupus Samples: Implications for Pathogenic Mechanism and Drug Targeting December 24, 2021
- Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis November 16, 2021
- The intersection of COVID-19 and autoimmunity October 28, 2021
- Antibody Responses to Epstein-Barr Virus in the Preclinical Period of Rheumatoid Arthritis Suggest the Presence of Increased Viral Reactivation Cycles October 4, 2021